CLINICAL TRIALS PROFILE FOR GELNIQUE
✉ Email this page to a colleague
All Clinical Trials for GELNIQUE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01192568 ↗ | Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder | Recruiting | Allergan | Phase 4 | 2011-05-02 | This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks. |
| NCT01192568 ↗ | Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder | Recruiting | Watson Pharmaceuticals | Phase 4 | 2011-05-02 | This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks. |
| NCT02386072 ↗ | A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) | Completed | Astellas Scientific & Medical Affairs, Inc. | 2015-01-05 | A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form) | |
| NCT02633371 ↗ | A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults | Completed | Society for Pediatric Dermatology | N/A | 2016-02-01 | This is a single-center, prospective, open-label, outpatient pilot study evaluating the efficacy and tolerability of oxybutynin gel for axillary hyperhidrosis. |
| NCT02633371 ↗ | A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults | Completed | University of Colorado, Denver | N/A | 2016-02-01 | This is a single-center, prospective, open-label, outpatient pilot study evaluating the efficacy and tolerability of oxybutynin gel for axillary hyperhidrosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GELNIQUE
Condition Name
Clinical Trial Locations for GELNIQUE
Trials by Country
Clinical Trial Progress for GELNIQUE
Clinical Trial Phase
Clinical Trial Sponsors for GELNIQUE
Sponsor Name
